omipalisib

Term ID

CHEBI:95093

Synonyms

• 2,4-difluoro-N-[2-methoxy-5-(4-pyridazin-4-ylquinolin-6-yl)pyridin-3-yl]benzenesulfonamide
• 2,4-difluoro-N-[2-methoxy-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl]benzenesulfonamide
• 2,4-difluoro-N-{2-methoxy-5-[4-(pyridazin-4-yl)quinolin-6-yl]pyridin-3-yl}benzene-1-sulfonamide
• 2,4-difluoro-N-{2-methoxy-5-[4-(pyridazin-4-yl)quinolin-6-yl]pyridin-3-yl}benzenesulfonamide
• GSK 212
• GSK 2126458
• GSK 458
• GSK-212
• GSK-2126458
• GSK-458
• GSK212
• GSK2126458
• GSK458
• omipalisib
• omipalisibum

Definition

A member of the class of quinolines that is quinoline which is substituted by pyridazin-4-yl and 5-[(2,4-difluorobenzene-1-sulfonyl)amino]-6-methoxypyridin-3-yl groups at positions 4 and 6, respectively. It is a highly potent inhibitor of PI3K and mTOR developed by GlaxoSmithKline and was previously in human phase 1 clinical trials for the treatment of idiopathic pulmonary fibrosis and solid tumors.

References

• cas:1086062-66-9
• chemspider:25027388
• drugbank:DB12703
• kegg.drug:D10718
• pdb-ccd:ZIG
• pubmed:21464613
• pubmed:22297110
• pubmed:22389471
• pubmed:24392766
• pubmed:24900173
• pubmed:25170609
• pubmed:25298748
• pubmed:25504751
• pubmed:25659532
• pubmed:26603258
• pubmed:26604245
• pubmed:26819001
• pubmed:27450049
• pubmed:28938574
• pubmed:29487419
• pubmed:29976629
• pubmed:30133440
• pubmed:30765508
• pubmed:31494146
• pubmed:32381012
• pubmed:32382996
• pubmed:32804918
• pubmed:33360802
• pubmed:33521022
• pubmed:34234012
• pubmed:34284231
• pubmed:34330845
• pubmed:34461940

Ontology

ChEBI  ( EBI )